EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Untangling the Biosimilars Interchangeability Puzzle: A Provocative Dive into Concepts and Terminology, and Developing a Strategy to Minimize Uncertainties from Interchangeability

Dalia Mahmoud Ghorab, Kholoud Mamdouh Abdelfattah, Howida Kamal Ibrahim, Soha Aly Aly Elmorsy

Therapeutic Innovation & Regulatory Science · 2025

DOI: 10.1007/s43441-025-00765-3 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2025. Verfasst von Dalia Mahmoud Ghorab und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr AlAiny Street, Cairo, 11562, Egypt. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Drug Substitution. Die Arbeit nennt 72 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The interchangeability of bioimilars (off-patent biologics) is a topic of ongoing debate in the literature. In the US, the FDA requires a demonstration of interchangeability before biosimilars can be interchanged on the market. However, this requirement is not mandated in other regions. Conversely, a joint statement from the Head of Medicines Agency and the EMA declared that once a biosimilar is approved in the EU it is interchangeable without the need for additional systematic switch studies to support the interchangeability at the prescriber level. The term interchangeability has a different meanings, depending on the country. To ensure the best interchange practice, a global definition of interchangeability is needed. Should biosimilars demonstrate both similarity to and interchangeability with the reference product before substitution or it is a matter of confidence of the healthcare professional, which can be attained through self-practice and available data from already switched patients? Would the recent calls and existing guidelines for using real-world data to support regulatory and clinical decisions be adequate for such interchangeable designation? In this review, we'll draw insights from the interchangeability of off-patent medicines (generics), and highlight the unique characteristics of biosimilars that differentiate them from generics affecting their interchangeability. We will highlight some regulatory standpoints and discuss clinical practices related to this practice. We will shed light on the procedures covered by this umbrella term, like switching and substitution, discuss the potential risks associated with the interchangeability of biosimilars, and suggest strategies to handle uncertainties from interchangeability practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsDrug SubstitutionHumansTerminology as TopicUnited StatesUnited States Food and Drug AdministrationDrug ApprovalUncertaintyTherapeutic Equivalency

Stichwörter der Autor:innen

Automatic substitutionInterchangeable productReal-world evidenceSwitching study

Substanzen

Biosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr AlAiny Street, Cairo, 11562, Egypt.
  • Central Administration of Biologicals and Innovative Products and Clinical Trials, Egyptian Drug Authority, Cairo, Egypt.
  • Pharmaceutics and Industrial Pharmacy Department, Faculty of Pharmacy, Cairo University, Kasr AlAiny Street, Cairo, 11562, Egypt. Howida.ibrahim@pharma.cu.edu.eg.
  • Pharmacology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.

Zitieren

APA

Ghorab, D. M., Abdelfattah, K. M., Ibrahim, H. K., & Elmorsy, S. A. A. (2025). Untangling the Biosimilars Interchangeability Puzzle: A Provocative Dive into Concepts and Terminology, and Developing a Strategy to Minimize Uncertainties from Interchangeability. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-025-00765-3

Vancouver

Ghorab DM, Abdelfattah KM, Ibrahim HK, Elmorsy SAA. Untangling the Biosimilars Interchangeability Puzzle: A Provocative Dive into Concepts and Terminology, and Developing a Strategy to Minimize Uncertainties from Interchangeability. Therapeutic Innovation & Regulatory Science. 2025. doi:10.1007/s43441-025-00765-3

BibTeX
@article{Ghorab2025,
  author = {Ghorab, Dalia Mahmoud and Abdelfattah, Kholoud Mamdouh and Ibrahim, Howida Kamal and Elmorsy, Soha Aly Aly},
  title = {Untangling the Biosimilars Interchangeability Puzzle: A Provocative Dive into Concepts and Terminology, and Developing a Strategy to Minimize Uncertainties from Interchangeability},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2025},
  doi = {10.1007/s43441-025-00765-3}
}
Kostenlos starten →